Literature DB >> 6892955

Developmental study of a lamellar body fraction isolated from human amniotic fluid.

M Oulton, T R Martin, G T Faulkner, D Stinson, J P Johnson.   

Abstract

Several properties of a pellet fraction obtained on centrifuging amniotic fluid at 10,000 X g for 20 min were investigated. From these analyses, we defined a developmental profile which appears to describe the maturational process of the fetal lung surfactant system. At 14 to 18 wk gestation, the pellet fraction consisted of membrane-bound vesicles without internal lamellae. The phospholipid composition did not resemble that of surfactant, the major phospholipid being sphingomyelin. This stage, designated as presurfactant, persisted until 30 to 32 wk gestation. After this time, the phospholipid concentration of the pellet fraction increased continuously throughout development, and gradual but continuous changes in phospholipid composition were observed. Lecithin and phosphatidylinositol increased between 30 and 35 wk gestation. Interruption of pregnancies at this stage, termed onset of surfactant synthesis, resulted in 100% incidence of respiratory distress syndrome. From 36 wk gestation to postterm, the pellet fraction contained structures with the characteristic morphology of the lamellar inclusion bodies. The presence of single membrane components in these preparations did not contribute to the phospholipid composition. Early formed lamellar bodies lacked phosphatidylglycerol and had a high content of phosphatidylinositol. Once phosphatidylglycerol appeared in the lamellar body fraction, it continued to increase, accompanied by a decrease in phosphatidylinositol with little change in lecithin. A phosphatidylglycerol value of greater than 1% of the total phospholipids appeared to represent the stage of maturity at which there was no risk of respiratory distress syndrome.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6892955     DOI: 10.1203/00006450-198005000-00004

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

1.  Cytodifferentiation of human fetal lung tissue following transplantation into "nude" mice.

Authors:  P Groscurth; G Töndury
Journal:  Anat Embryol (Berl)       Date:  1982

2.  Androgen regulation of lung lipids in the male rat.

Authors:  M S Ojeda; N Gomez; M S Giménez
Journal:  Lipids       Date:  1997-01       Impact factor: 1.880

3.  Differentiation of type II cells of human fetal lung in vitro.

Authors:  J M Snyder; J M Johnston; C R Mendelson
Journal:  Cell Tissue Res       Date:  1981       Impact factor: 5.249

4.  Bovine pulmonary surfactant: chemical composition and physical properties.

Authors:  S Yu; P G Harding; N Smith; F Possmayer
Journal:  Lipids       Date:  1983-08       Impact factor: 1.880

5.  Effects of smoke inhalation on alveolar surfactant subtypes in mice.

Authors:  M R Oulton; D T Janigan; J M MacDonald; G T Faulkner; J E Scott
Journal:  Am J Pathol       Date:  1994-10       Impact factor: 4.307

6.  Effects of smoke inhalation on surfactant phospholipids and phospholipase A2 activity in the mouse lung.

Authors:  M Oulton; H K Moores; J E Scott; D T Janigan; R Hajela
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

7.  Mouse alveolar surfactant: characterization of subtypes prepared by differential centrifugation.

Authors:  M Oulton; J MacDonald; D T Janigan; G T Faulkner
Journal:  Lipids       Date:  1993-08       Impact factor: 1.880

8.  Human embryonic lung epithelial tips are multipotent progenitors that can be expanded in vitro as long-term self-renewing organoids.

Authors:  Marko Z Nikolić; Oriol Caritg; Quitz Jeng; Jo-Anne Johnson; Dawei Sun; Kate J Howell; Jane L Brady; Usua Laresgoiti; George Allen; Richard Butler; Matthias Zilbauer; Adam Giangreco; Emma L Rawlins
Journal:  Elife       Date:  2017-06-30       Impact factor: 8.140

Review 9.  Human lung development: recent progress and new challenges.

Authors:  Marko Z Nikolić; Dawei Sun; Emma L Rawlins
Journal:  Development       Date:  2018-08-15       Impact factor: 6.868

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.